IOBT vs. LIFE, DRRX, NKTR, PGEN, ANRO, ORGO, SBTX, URGN, QURE, and VNDA
Should you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include aTyr Pharma (LIFE), DURECT (DRRX), Nektar Therapeutics (NKTR), Precigen (PGEN), Alto Neuroscience (ANRO), Organogenesis (ORGO), Silverback Therapeutics (SBTX), UroGen Pharma (URGN), uniQure (QURE), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "medical" sector.
IO Biotech (NASDAQ:IOBT) and aTyr Pharma (NASDAQ:LIFE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
54.8% of IO Biotech shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 2.3% of IO Biotech shares are held by insiders. Comparatively, 3.7% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
aTyr Pharma received 408 more outperform votes than IO Biotech when rated by MarketBeat users. However, 87.50% of users gave IO Biotech an outperform vote while only 60.98% of users gave aTyr Pharma an outperform vote.
IO Biotech has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
In the previous week, IO Biotech and IO Biotech both had 3 articles in the media. IO Biotech's average media sentiment score of 0.99 beat aTyr Pharma's score of 0.00 indicating that IO Biotech is being referred to more favorably in the media.
IO Biotech presently has a consensus target price of $9.67, suggesting a potential upside of 649.35%. aTyr Pharma has a consensus target price of $25.50, suggesting a potential upside of ∞. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than IO Biotech.
aTyr Pharma's return on equity of -56.92% beat IO Biotech's return on equity.
aTyr Pharma has higher revenue and earnings than IO Biotech. IO Biotech is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
aTyr Pharma beats IO Biotech on 10 of the 14 factors compared between the two stocks.
Get IO Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IO Biotech Competitors List
Related Companies and Tools
